Uploading insulin.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 13:45:06 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 0 TO 0
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 13:45:13 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4 TO ITERATE

100.0% PROCESSED 4 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.02

L3 2 SEA SSS FUL L1

=> d l3

L3 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2002 ACS
RN 309932-60-3 REGISTRY
CN Benzenesulfonic acid, 3,3'-[carbonylbis[imino(4-hydroxy-7,2-naphthalenediyl)sulfonylimino]]bis[6-chloro- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C33 H24 Cl2 N4 O13 S4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1962 TO DATE)
3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> d 2

L3 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2002 ACS
RN 309932-59-0 REGISTRY
CN Benzenesulfonic acid, 3,3'-[carbonylbis(imino-7,2-naphthalenediylsulfonylimino)]bis[6-chloro- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C33 H24 Cl2 N4 O11 S4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> fil embase biosis medline caplus uspatfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	144.96	145.17

FILE 'EMBASE' ENTERED AT 13:47:18 ON 18 NOV 2002

FILE 'BIOSIS' ENTERED AT 13:47:18 ON 18 NOV 2002

FILE 'MEDLINE' ENTERED AT 13:47:18 ON 18 NOV 2002

FILE 'CAPLUS' ENTERED AT 13:47:18 ON 18 NOV 2002

FILE 'USPATFULL' ENTERED AT 13:47:18 ON 18 NOV 2002

=> s 309932-59-0/rn or 309932-60-3/rn
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
L4 6 309932-59-0/RN OR 309932-60-3/RN

=> dup rem l4
PROCESSING COMPLETED FOR L4
L5 5 DUP REM L4 (1 DUPLICATE REMOVED)

=> d l5 1-5 ab bib kwic

L5 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 1
AB A method is provided for detg. whether a compd. is an insulin receptor kinase activator. The methodol. of the invention comprises administering the compd. to a non-human mammal concurrently treated with an HIV protease inhibitor; administering glucose to the mammal; and measuring the level of plasma insulin or plasma glucose in the mammal, where a reduced level of plasma insulin or plasma glucose in the mammal compared to a comparable mammal that has been treated with the HIV protease inhibitor and administered the glucose, but not administered the compd., indicates that the compd. is an insulin receptor kinase activator. Reversal of protease inhibitor-mediated insulin resistance in normal rats by I (prepn. included) is described.
AN 2002:794315 CAPLUS
DN 137:289023
TI Method for determining whether a compound is an insulin receptor kinase activator
IN Manchem, Prasad V. V. S. V.; Lum, Robert T.; Schow, Steven R.
PA USA
SO U.S. Pat. Appl. Publ., 6 pp., Cont.-in-part of U. S. Ser. No. 977,059.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002151542	A1	20021017	US 2002-115595	20020402
	US 2002061927	A1	20020523	US 2001-977059	20011011
PRAI	US 2000-239636P	P	20001011		
	US 2001-977059	A2	20011011		

app. 10/115,595

IT **309932-60-3P**
RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(insulin receptor kinase activator detn.)

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2002 ACS
AB The invention comprises the use of insulin receptor activating compds., optionally in conjunction with insulin, for the treatment of HIV protease inhibitor-induced metabolic disorders. Any insulin receptor activating compds. suitable for the practice of the invention and other addnl. dinaphthalene urea derivs. are disclosed. Methods of treating a person suffering from HIV protease inhibitor-induced metabolic disorders such as lipodystrophy, hypertriglyceridemia, insulin resistance, hyperglycemia, diabetes and ketoacidosis are also provided.
AN 2002:293499 CAPLUS
DN 136:304094
TI Insulin receptor activators for the treatment of metabolic disorders in humans resulting from treatment of HIV infection with HIV protease inhibitors
IN Manchem, Prasad V. V. S. V.; Lum, Robert T.; Schow, Steven R.
PA Telik, Inc., USA
SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002030514	A2	20020418	WO 2001-US42733	20011010
	W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	FR 2814953	A1	20020412	FR 2001-13040	20011010
	AU 2002011922	A5	20020422	AU 2002-11922	20011010
PRAI	US 2000-239636P	P	20001011		
	WO 2001-US42733	W	20011010		

OS MARPAT 136:304094
IT **309932-60-3P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(insulin receptor activators for treatment of metabolic disorders in humans resulting from treatment of HIV infection with HIV protease inhibitors)

L5 ANSWER 3 OF 5 USPATFULL
AB Methods of treating a person suffering from HIV protease inhibitor-induced metabolic disorders such as lipodystrophy, hypertriglyceridemia, insulin resistance, hyperglycemia, diabetes and ketoacidosis, comprise treatment with an insulin receptor activating compound, optionally in conjunction with insulin. In general, any insulin receptor activating compound is suitable for the practice of the

invention; and preferred compounds are disclosed.
AN 2002:119938 USPATFULL
TI Insulin receptor activators for the treatment of metabolic disorders induced by treatment with HIV protease inhibitors
IN Manchem, Prasad V.V.S.V., South San Francisco, CA, UNITED STATES
Lum, Robert T., Palo Alto, CA, UNITED STATES
Schow, Steven R., Redwood Shores, CA, UNITED STATES
PI US 2002061927 A1 20020523
AI US 2001-977059 A1 20011011 (9)
PRAI US 2000-239636P 20001011 (60)
DT Utility
FS APPLICATION
LREP HELLER EHRMAN WHITE & MCAULIFFE LLP, 275 MIDDLEFIELD ROAD, MENLO PARK, CA, 94025-3506
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 1249
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **309932-60-3P**
(insulin receptor activators for treatment of metabolic disorders in humans resulting from treatment of HIV infection with HIV protease inhibitors)

my app. 09/977,059

L5 ANSWER 4 OF 5 USPATFULL
AB Compounds of formula I are useful for treating conditions associated with hyperglycemia, especially Type II diabetes. These compounds are useful in stimulating the kinase activity of the insulin receptor, activating the insulin receptor, and stimulating the uptake of glucose. Pharmaceutical compositions comprising the antidiabetic compounds are also disclosed.
AN 2002:254503 USPATFULL
TI Naphthalene ureas as glucose uptake enhancers
IN Spevak, Wayne R., Albany, CA, United States
Shi, Songyuan, Fremont, CA, United States
Manchem, Prasad V. V. S. V., South San Francisco, CA, United States
Kozlowski, Michael R., Palo Alto, CA, United States
Schow, Steven R., Redwood Shores, CA, United States
Lum, Robert T., Palo Alto, CA, United States
PA Telik, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6458998 B1 20021001
AI US 2000-579279 20000525 (9)
PRAI US 1999-136128P 19990526 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Gitomer, Ralph; Assistant Examiner: Chaudhry, Mahreen
LREP Heller Ehrman White & McAuliffe LLP
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 16 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 2964
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 20324-87-2P 309931-84-8P 309931-85-9P 309931-88-2P 309931-89-3P
309931-90-6P 309931-93-9P 309931-94-0P 309931-95-1P 309931-96-2P
309931-97-3P 309931-98-4P 309931-99-5P 309932-00-1P 309932-01-2P
309932-02-3P 309932-03-4P 309932-04-5P 309932-05-6P 309932-06-7P
309932-07-8P 309932-08-9P 309932-09-0P 309932-10-3P 309932-11-4P
309932-12-5P 309932-13-6P 309932-14-7P 309932-15-8P 309932-16-9P
309932-17-0P 309932-18-1P 309932-19-2P 309932-20-5P 309932-21-6P
309932-22-7P 309932-23-8P 309932-24-9P 309932-25-0P 309932-26-1P

309932-27-2P 309932-29-4P 309932-30-7P 309932-31-8P 309932-33-0P
309932-34-1P 309932-36-3P 309932-38-5P 309932-40-9P 309932-42-1P
309932-44-3P 309932-45-4P 309932-46-5P 309932-47-6P 309932-48-7P
309932-49-8P 309932-50-1P 309932-51-2P 309932-52-3P 309932-53-4P
309932-54-5P 309932-55-6P 309932-56-7P 309932-57-8P 309932-58-9P
309932-59-0P 309932-60-3P 309932-63-6P 309932-64-7P
309932-65-8P 309932-66-9P 309932-67-0P 309932-68-1P 309932-69-2P
309932-70-5P 309932-71-6P 309932-73-8P 309932-74-9P 309932-75-0P
309932-76-1P 309932-77-2P 309932-78-3P 309932-79-4P 309932-81-8P
309932-84-1P 309932-85-2P 309932-86-3P 309932-87-4P 309932-88-5P
309932-89-6P 309932-90-9P 309932-91-0P 309932-92-1P 309932-93-2P
309932-94-3P 309932-95-4P 309932-96-5P 309932-97-6P 309932-98-7P
309932-99-8P 309933-00-4P 309933-01-5P 309933-02-6P 309933-03-7P
309933-04-8P 309933-05-9P 309933-06-0P 309933-07-1P 309933-08-2P
(prepn. of novel dinaphthyl ureas as glucose uptake enhancers)

L5 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2002 ACS

AB The title compds. [I; R1, R2 = SO2NR72, CONR72, NR7SO2R7, etc.; R5, R6 = H, alkyl, CN, etc.; R7 = H, alkyl, aryl, etc.; Y = a non-interfering substituent which is not linked to the naphthalene ring via an azo or amide linkage; x = 0-2; the linker connects a carbon designated as c to a carbon designated as d, and is NR3C(:K)NR4 (wherein K = O, S, NH, etc.; R3, R4 = H, alkyl; R3, R4 together = (CH2)2, (CH2)3, (CH2)4, etc.), N:C(NR112)NR4 (R11 = H, CN, alkyl); NR3C(NR112):N, etc.], useful for treating conditions assocd. with hyperglycemia, esp. Type II diabetes, were prepd. and formulated. E.g., a multi-step synthesis of the urea II which produced a 13% decrease in blood glucose levels, a 42% decrease in plasma insulin levels, and a 15% decrease in plasma triglyceride levels in the ob/ob mouse model of Type II diabetes, was given. The compds. I are useful in stimulating the kinase activity of the insulin receptor, activating the insulin receptor, and stimulating the uptake of glucose.

AN 2000:842102 CAPLUS
DN 134:17320

TI Preparation of novel dinaphthyl ureas as glucose uptake enhancers

IN Spevak, Wayne; Lum, Robert T.; Shi, Songyuan; Manchem, Prasad; Kozlowski, Michael R.; Schow, Steven R.
PA Telik, Inc., USA

SO PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000071506	A2	20001130	WO 2000-US14644	20000525
	WO 2000071506	A3	20010809		

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

	EP 1181271	A2	20020227	EP 2000-936360	20000525

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

```
     BR 2000011550      A    20020604       BR 2000-11550     20000525
     US 6458998         B1   20021001       US 2000-579279    20000525
     NO 2001005713      A    20011220       NO 2001-5713      20011123
PRAI US 1999-136128P    P    19990526
     WO 2000-US14644    W    20000525
OS   MARPAT 134:17320
IT   20324-87-2P   309931-84-8P   309931-85-9P   309931-88-2P   309931-89-3P
     309931-90-6P   309931-93-9P   309931-94-0P   309931-95-1P   309931-96-2P
     309931-97-3P   309931-98-4P   309931-99-5P   309932-00-1P   309932-01-2P
     309932-02-3P   309932-03-4P   309932-04-5P   309932-05-6P   309932-06-7P
     309932-07-8P   309932-08-9P   309932-09-0P   309932-10-3P   309932-11-4P
     309932-12-5P   309932-13-6P   309932-14-7P   309932-15-8P   309932-16-9P
     309932-17-0P   309932-18-1P   309932-19-2P   309932-20-5P   309932-21-6P
     309932-22-7P   309932-23-8P   309932-24-9P   309932-25-0P   309932-26-1P
     309932-27-2P   309932-29-4P   309932-30-7P   309932-31-8P   309932-33-0P
     309932-34-1P   309932-36-3P   309932-38-5P   309932-40-9P   309932-42-1P
     309932-44-3P   309932-45-4P   309932-46-5P   309932-47-6P   309932-48-7P
     309932-49-8P   309932-50-1P   309932-51-2P   309932-52-3P   309932-53-4P
     309932-54-5P   309932-55-6P   309932-56-7P   309932-57-8P   309932-58-9P
     309932-59-0P 309932-60-3P   309932-63-6P   309932-64-7P
     309932-65-8P   309932-66-9P   309932-67-0P   309932-68-1P   309932-69-2P
     309932-70-5P   309932-71-6P   309932-73-8P   309932-74-9P   309932-75-0P
     309932-76-1P   309932-77-2P   309932-78-3P   309932-79-4P   309932-81-8P
     309932-84-1P   309932-85-2P   309932-86-3P   309932-87-4P   309932-88-5P
     309932-89-6P   309932-90-9P   309932-91-0P   309932-92-1P   309932-93-2P
     309932-94-3P   309932-95-4P   309932-96-5P   309932-97-6P   309932-98-7P
     309932-99-8P   309933-00-4P   309933-01-5P   309933-02-6P   309933-03-7P
     309933-04-8P   309933-05-9P   309933-06-0P   309933-07-1P   309933-08-2P
     RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
     study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
     BIOL (Biological study); PREP (Preparation); USES (Uses)
        (prepn. of novel dinaphthyl ureas as glucose uptake enhancers)


=> fil marpat
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    23.48     168.65

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -1.86      -1.86

FILE 'MARPAT' ENTERED AT 13:51:02 ON 18 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE CONTENT: 1988-PRESENT (VOL 104 ISS 15-VOL 137 ISS 20)(20021117/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US    6465697 15 OCT 2002
DE   10119728 31 OCT 2002
EP    1253153 30 OCT 2002
JP 2002308805 23 OCT 2002
WO 2002085929 31 OCT 2002
```

Structure search limits have been raised. See HELP SLIMIT for the new, higher limits.

```
=> s l1
SAMPLE SEARCH INITIATED 13:51:07 FILE 'MARPAT'
SAMPLE SCREEN SEARCH COMPLETED -    159 TO ITERATE

100.0% PROCESSED     159 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.02

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         2428 TO     3932
PROJECTED ANSWERS:               0 TO        0

L6            0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 13:51:16 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED -   2880 TO ITERATE

100.0% PROCESSED    2880 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.18

L7            0 SEA SSS FUL L1

=>
```